Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles.

Herrmann K, Shan K, Brunell SC, Chen S

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Oct 2014Cited by 7 (Europe PMC)

PMID25100363DOI10.4158/ep13477.orPepBankPUB-25100363

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In the type 2 diabetes clinical practice trial, pramlintide was associated with decreased A1C across baseline insulin-dose tertiles.
In plain wordsIn the type 2 diabetes practice trial, pramlintide was linked to lower A1C across initial insulin-dose groups.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseA1C in clinical practice trial
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, in the clinical practice trial, pramlintide was associated with decreases in A1C, body weight, and total daily insulin use across the tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
Report a problemFND-2510036303
02HumanNon-randomized trialEfficacy outcome
In the type 2 diabetes clinical practice trial, pramlintide was associated with decreased body weight across baseline insulin-dose tertiles.
In plain wordsIn the type 2 diabetes practice trial, pramlintide was linked to lower weight across initial insulin-dose groups.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight in clinical practice trial
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, in the clinical practice trial, pramlintide was associated with decreases in A1C, body weight, and total daily insulin use across the tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
Report a problemFND-2510036304
03HumanNon-randomized trialEfficacy outcome
In the type 2 diabetes clinical practice trial, pramlintide was associated with decreased daily insulin use across baseline insulin-dose tertiles.
In plain wordsIn the type 2 diabetes practice trial, pramlintide was linked to lower daily insulin use across initial insulin-dose groups.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal daily insulin use in clinical practice trial
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, in the clinical practice trial, pramlintide was associated with decreases in A1C, body weight, and total daily insulin use across the tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
Report a problemFND-2510036305
04HumanOther designEfficacy outcome
In pivotal trials of type 2 diabetes, pramlintide reduced body weight similarly across baseline insulin-dose tertiles.
In plain wordsIn type 2 diabetes trials, weight fell similarly with pramlintide across groups defined by initial insulin dose.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight across insulin tertiles in pivotal trials
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In the pivotal trials, both glycated hemoglobin (A1C) and body weight decreased similarly across tertiles with pramlintide.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
Report a problemFND-2510036302
05HumanOther designSafety outcome
Across the type 2 diabetes trials, the most common adverse events during pramlintide therapy were gastrointestinal.
In plain wordsIn type 2 diabetes trials, the most common adverse events with pramlintide affected the digestive system.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Overall, the most common adverse events were gastrointestinal in nature, and the rate of severe hypoglycemia was low.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
Report a problemFND-2510036306
06HumanOther designSafety outcome
Across the type 2 diabetes trials, the rate of severe hypoglycemia during pramlintide therapy was low.
In plain wordsIn type 2 diabetes trials, severe low blood sugar was uncommon during pramlintide therapy.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSevere hypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Overall, the most common adverse events were gastrointestinal in nature, and the rate of severe hypoglycemia was low.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
Report a problemFND-2510036307

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

07HumanNot a test of Pramlintide (Symlin) aloneOther designEfficacy outcome
In a post hoc analysis of pooled pivotal trials, A1C decreased similarly across insulin-dose tertiles during pramlintide therapy. A1C also decreased slightly with placebo.
In plain wordsA1C decreased across insulin-dose groups during pramlintide therapy. It also decreased slightly with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseA1C across insulin tertiles in pivotal trials
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In the pivotal trials, both glycated hemoglobin (A1C) and body weight decreased similarly across tertiles with pramlintide.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
Summary · context
In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2510036301

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.